News Releases

Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, and CRP. This study demonstrated that CKD-induced IL-1β activates NLRP3 inflammasomes in the heart’s atria to trigger inflammation promoting the onset and
Sep 22, 2023
Activation of multiple inflammasome pathways contributes to pathological inflammation in neurodegenerative (“CNS”) diseases, such as amyotrophic lateral sclerosis (“ALS”) This study showed that NLRP3 inhibition alone was inadequate to address CNS inflammation in a mouse model of ALS ZyVersa is
Sep 12, 2023
Mechanical stress on the heart, such as high blood pressure, initiates NLRP3-induced inflammation through heart-brain interactions, causing heart enlargement (hypertrophic heart disease) Mechanical stress on the heart triggers neural signals that contribute to NLRP3 inflammasome activation and
Jul 10, 2023
Lupus Nephritis (“LN”) is characterized by inflammation in the kidney, protein leakage into the urine (“proteinuria”), and progressive kidney damage NLRP3 inflammasomes were extensively activated in the kidneys of LN patients, with higher levels of activation in patients with more severe forms of
Jun 28, 2023
PAD, characterized by vascular inflammation and associated calcification, affects 8.5 million people in the United States and contributes to more than 50,000 limb amputations annually, yet there are no specific pharmacologic treatments ZyVersa is developing Inflammasome ASC Inhibitor IC 100 for
Jun 20, 2023
Displaying 31 - 40 of 85